About HUTCHMED Company

Hutchison Pharmaceutical is an innovative biomedical company in the commercialization stage, aiming to become a global leader in the discovery, development and commercialization of targeted therapies and immunotherapy treatments for cancer and immune diseases. We are one of the first innovative pharmaceutical R&D companies in China to focus on the global market. Over the past 20 years, we have built a fully integrated R&D innovation platform with world-class discovery and development capabilities. As of 2020, we currently have a research and development team composed of about 600 professionals and 10 clinical-stage innovative anti-cancer drugs that are undergoing clinical research worldwide. We have also established a deep and profitable commercial platform in the Chinese market to manufacture, market and distribute prescription drugs and consumer health products in China, as well as our two innovative oncology drugs that have already been marketed in China — iutac (fruquintinib capsules) and suteta (surufatinib capsules). We are also expanding our commercialization footprint further into the US and Europe. Hutchison Pharmaceutical is listed on the Nasdaq Global Select Market and the London Alternative Investment Market (NASDAQ/London Stock Exchange: HCM).